Universiteit Gent

Vib Vzw

Centre National De La Recherche Scientifique

Orionis Biosciences Bv

Centre Hospitalier Régional Universitaire De Montpellier

Universitè De Montpellier

Universite Montpellier 2

Sarah Gerlo

Jan Tavernier

Nikolai Kley

Gilles Uze

Anje Cauwels

Franciane Paul

Jennyfer Bultinck

Yann Bordat

Frank Peelman

Gilles Uzé

The present invention relates, in part, to agents that bind C-type lectin domain containing 9A (Clec9A) and their use as diagnostic and therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the Clec9A binding agents and their use in the treatment of various diseases.

CLEC9A binding agents

The present invention relates to a fusion protein comprising at least two cytokines, of which at least one is a modified cytokine with a strongly reduced binding affinity to its receptor, or to one of its receptors. Preferably, both cytokines are connected by a linker, preferably a GGS linker. The invention relates further to said fusion protein for use in treatment of diseases.

Fusokines involving cytokines with strongly reduced receptor binding affinities

The present invention relates, in part, to agents that bind CD8 and their use as therapeutic and diagnostic agents. The present invention further relates to pharmaceutical compositions comprising the CD8 binding agents and their use in the treatment of various diseases, including, for example, cancers.

CD8 binding agents

The present invention relates, in part, to agents that bind Clec9A and their use as diagnostic and therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the Clec9A binding agents and their use in the treatment of various diseases.

Clec9A binding agents

The present disclosure relates to a modified Interleukin-1 (IL-1) family member cytokine, with reduced activity via its cytokine receptor, wherein said interleukin-1 family member cytokine is specifically delivered to target cells. Preferably, the IL-1 family member cytokine is a mutant, more preferably it is a mutant IL-1 with low affinity to the IL-1 receptor, wherein said mutant IL-1 is specifically delivered to target cells. The targeting is preferably realized by fusion of the modified IL-1 family member cytokine to a targeting moiety, preferably an antibody or antibody-like molecule. The disclosure relates further to the use of such targeted modified IL-1 family member cytokine to treat diseases.

Targeted modified IL-1 family members

Growing community of inventors

Ghent, Belgium

Sarah Gerlo